Ignite Creation Date:
2024-05-05 @ 5:00 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00361283
Status:
COMPLETED
Last Update Posted:
2012-05-15
First Post:
2006-08-04
Brief Title:
Systemic Immunomodulatory Effects and Pharmacogenetics of Atorvastatin in Early Atherosclerosis
Sponsor:
University of Florida
Organization:
University of Florida
Study Overview
Official Title:
Systemic Immunomodulatory Effects and Pharmacogenetics of Atorvastatin in Early Atherosclerosis
Status:
COMPLETED
Status Verified Date:
2012-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to test whether atorvastatin also known as Lipitor has anti-inflammatory effects in people with no known heart disease or high cholesterol We also are investigating whether or not genetic differences between people plays a role in the drug response
Detailed Description:
All subjects received 16 weeks of Atorvastatin after a two week run in Key dependent variables were the 16 week value minus the baseline value post run-in Last observation carried forward was used for missing values The key comparisons are for two groups OATP1B1 reduced carriers and on-carriers and their association with Cytokines and Lipids Secondarily we were interested in changes over the 16 weeks for the pooled sample irrespective of genetics
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None